[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567988":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":32,"centralContacts":36,"locations":42,"responsibleParty":69,"collaborators":22,"id":71,"slug":22,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":22,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":22,"enrollmentInfo":79,"targetDuration":22,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":22,"overallStatus":45,"whyStopped":22,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University of Wisconsin, Madison","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Fibroblast activation protein inhibitor (FAPI)","EXPERIMENTAL","FAPI radiotracer will be used during PET",[13,14,15],"Radiation: FAPI","Procedure: Positron Emission Tomography (PET)","Procedure: Magnetic Resonance Imaging",[17,23,28],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"RADIATION","FAPI","5 +\u002F- 2 mCi of Ga-FAPI-46",[9],null,{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":22},"PROCEDURE","Positron Emission Tomography (PET)","Undergo PET scan",[9],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":22},"Magnetic Resonance Imaging","Undergo MRI scan",[9],[33],{"name":34,"affiliation":5,"role":35},"Ali Pirasteh, MD","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":22,"email":41},"Radiology Studies","CONTACT","608-282-8349","Radstudy@uwhealth.org",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"University of Wisconsin","RECRUITING","Madison","Wisconsin","53705","United States",{"type":51,"coordinates":52},"Point",[53,54],-89.40123,43.07305,{"lat":54,"lon":53},[57,58,61,63,65,67],{"name":34,"role":35,"phone":22,"phoneExt":22,"email":22},{"name":59,"role":60,"phone":22,"phoneExt":22,"email":22},"Joshua Lang, PhD","SUB_INVESTIGATOR",{"name":62,"role":60,"phone":22,"phoneExt":22,"email":22},"Diego Hernando, PhD",{"name":64,"role":60,"phone":22,"phoneExt":22,"email":22},"Steven Cho, MD, PhD",{"name":66,"role":60,"phone":22,"phoneExt":22,"email":22},"Glenn Liu, MD",{"name":68,"role":60,"phone":22,"phoneExt":22,"email":22},"Alan McMillan, PhD",{"type":70,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100567988",false,"NCT06675357","Using FAPI PET\u002FMRI to Evaluate Prostate Cancer","Novel FAP-targeted Approach to Imaging Patients With or High-risk for Metastatic Prostate Cancer","Inclusion Criteria:\n\n* Age 18 years or older\n* Able and willing to provide informed consent\n* Known diagnosis of prostate cancer\n* Scheduled for or recently performed (within 4 weeks) standard-of-care PSMA PET\n* Optional: Scheduled for SOC biopsy of an established or suspected non-osseous, non-nodal metastases.\n* Willing and able to undergo PET\u002FMRI as part of this research\n\nExclusion Criteria:\n\n* Unable or unwilling to provide informed consent\n* Contraindication(s) to or inability to undergo PET\u002FMRI\n* Participants for whom PET\u002FMRI will delay timely delivery of treatment\n* Participants requiring intravenous (IV) conscious sedation for imaging care; those requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:\n* Have their own prescription for the medication\n* The informed consent process is conducted prior to the self-administration of this medication\n* Come to the research visit with a driver","ALL","18 Years",{"count":80,"type":81},30,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer.\n\nParticipants will undergo two PET\u002FMRI scans during two research visits, each of which may last up to 2.5 hours.",[87,88],"Prostate Cancer Metastatic Disease","Prostate Cancers","2026-06-09",{"date":91,"type":92},"2026-06-10","ACTUAL",{"date":94,"type":92},"2026-02-27",{"date":96,"type":81},"2027-01",{"name":5,"class":6},1]